Cumulative Index 1986

Volume 6

March	ADVANCES IN IMMUNOPATHOLOGY, pp. 1–201
June	OFFICE PRACTICE OF LABORATORY MEDICINE, pp. 203–399
September	ELECTROPHORESIS OF SERUM PROTEINS AND ISOENZYMES, pp. 401–612
December	CLINICAL AND ECONOMIC PRACTICE OF QUALITY CONTROL, pp. 613–833

Note: Page numbers of article titles are in **boldface** type.

Abbott Yeast Identification system, 660–661
Accu-chek bG, 234
Acetest, 224
Acetoacetate, 223
Acetone, 223
Acid phosphatase, electrophoresis of, **507–523**
Acquired immune deficiency syndrome, (AIDS), **3–26**
Acrylamide electrophoresis, of amylase isoenzymes, 591, 593
Activation, of complement, 139–146
  transcriptional, of oncogenes, 175
Acute glomerulonephritis, C3 complement and, 448
Acute myocardial infarction, common causes of false-positive CK-MB test for, **577–581**
  serum creatine kinase levels in, 556–558
Administrative rules, laboratory test ordering and, 392
Adult serum alkaline phosphatase, clinical significance of increased or decreased levels of, **525–532**
  in osseous disease, 527–528
Agammaglobulinemia, monoclonal gammopathy and, 454
Agarose, as electrophoretic support medium, 403–407
Age, and serum immunoglobulin E, 119
Albumin, and problems, in electrophoretic process, 431–432
  CSF, as index of blood–brain barrier integrity, 459
  serum, abnormalities of, electrophoretic screening for, 441–443
Alcoholic acute pancreatitis, and GGT_3 isoenzyme, 537
Alcoholic hepatitis, and GGT_2 isoenzyme, 536–537
Alkaline phosphatase, acetylation of, 515
  and intracellular metabolism, 501
  clinical significance of increased or decreased level of, **525–532**
  clinical use of, **491–506**
  electrophoresis of, **507–523**
  in hepatic cancer, 499
  in liver cholestasis, 497–499
  intestinal isoenzyme of, 500
  PAGE separation of, analysis of, 494–500
  placental, allelozymes of, 514–515
  polyacrylamide gel technique in electrophoresis of, 510
Alkaline phosphatase isoenzymes, clinical use of, **491–506**
  "placental-like", 517
Allergen-specific immunoglobulin E, assay of, 123–130
Allergen-specific immunoglobulin G, assay of, 130–134

Allergy(ies), **117–138**
Alpha-amylase, electrophoretic assays of, 583–599
$Alpha_1$-antitrypsin deficiency, serum protein electrophoresis screening for, 443–444
Alpha-chain disease, 447–478
$Alpha_1$ globulin, electrophoretic screening for, 443–444
$Alpha_2$ globulin, electrophoretic screening for abnormal levels of, 444–446
Alpha–heavy chain disease, **477–489**
Alpha–heavy chain disease protein, 478–479
Amido Black, in electrophoretic process, 430–431
Amines, in renal disease, 59–60
Amylase, urine, measurement of, 262
Amylase isoenzymes, electrophoretic assays of, **583–599**
Anaerobe(s), identification of, systems for, 654–655
Analytic process, quality assurance of, **613–623**
Analyzers, for doctor's office testing, **305–315**
Anemia, hemolytic, serum protein electrophoresis of beta globulins and, 447
iron deficiency, decreased transferrin levels and, 447
screening for, 250
Angioedema, hereditary, complement system and, 142
Antibody(ies), antiglomerular basement membrane, in renal disease, 62
immunoglobulin E, 117–130
to nuclear antigens, in systemic rheumatic disease, **41–53**
Anticoagulants, circulating, 160–163
Antiepidermal skin test, immunofluorescent, 85
Antigen(s), detection of in body fluids, tests for, 659–660
Antigen–antibody complexes, coagulation and 159–163
Antigenicity, of complement components, assays for, 149–150
Antigens, microbial, in renal disease, 63–64
nuclear, autoantibodies to, in systemic rheumatic disease, **41–53**
nucleolar, antibodies to, 48–49
Antiglomerular basement membrane antibodies, in renal disease, 62
Antiglomerular basement membrane glomerulonephritis, 65–66
Antipeptide antibodies, in oncogene identification, 188
Arthritis, rheumatoid, **27–40**
immunofluorescent studies in, 92–93
serum immunoglobulin E and, 121
Assay(s). See specific types.
Atransferrinemia, congenital, serum protein electrophoresis and, 447
Audit with feedback, for office laboratories, 391
Autoimmune antiglomerular basement membrane glomerulonephritis, 66
Autoimmune demyelination, 468
Autoimmune diseases, complement system and, 142
immunoglobulin–alkaline phosphate complexes and, 501
Autoimmune mechanisms, in rheumatoid arthritis, 30–31
Average of normal(s) (AON), for quality control, 778–780
in patient data, 720–726

Bac-Tec system, for detection of bacterial growth, 661
Bacteria, in rheumatoid arthritis, 27–29
Bacterial identification systems, in microbiology, 650–662
Bacteriuria, rapid screening methods for, 296
Bac-T-Screen, 296
Basophils, in renal disease, 58
B-cell lymphoma(s), in acquired immune deficiency syndrome, 15
BCIP, in alkaline phosphatase isoenzyme separation, 493–494
Bence Jones lambda bands, agarose gel in detection of, 404–405
Benign chronic bullous disease of childhood, immunofluorescent studies in, 95
Berger's IgA-associated glomerulonephritis, 68–70
Bessey-Lowry-Brock method, of alkaline phosphatase isoenzyme separation, 492
Beta-gamma bridge, 448–450
Beta globulin, electrophoretic screening for abnormalities of, 447–448
Beta-hydroxybutyric acid, 223
Biclonal gammopathies, 417, 418
Bilirubin, urine, 258–259
Bioluminescence screening, 296–297
Biopsy, in immunofluorescent studies, 85–88
Bisalbuminemia, electrophoretic pattern of, 441–442
Biuret, in electrophoretic process, 430
Bleeding time test, 278–279
Blood, coagulation of, **157–165.** See also *Coagulation.*
immunoglobulin E in, 123–130
occult, test for, 255–256
transfusion of, acquired immune deficiency syndrome and, 9
Blood bank(s), changes in, 694
crossmatching in, 694–696
equipment and reagent quality assurance for, 690–691
inspection and accreditation programs for, 689–690

Blood bank(s) *Continued)*
quality control in, **689–696**
personnel, 691–692
transfusion reactions, 692–693
transfusion quality assurance in, 692–694
Blood–brain barrier, CSF and, 458–459
Blood cell(s), white, in blood smear, estimating of, 280
Blood cell counting, 273–276
Blood culture isolation systems, unconventional, 661–662
Blood smear, peripheral, 279–281
Blood testing, in office, **273–289**
Bone alkaline phosphatase, methods for improving electrophoretic resolution of, 511, 512
Bone marrow, in acquired immune deficiency syndrome, 12
Bone marrow serum, creatine kinase activity in, 552
Brain, creatine kinase activity in, 550
in multiple sclerosis, 105–106, 457, 458
Bromphenol Blue, in serum protein electrophoresis prestaining, 429
Buffers, and electrophoretic process, 430
in alkaline phosphatase isoenzyme separation, 493–494
Bullous diseases, immunofluorescent studies in, 93–97
Bullous lupus erythematosus, immunofluorescent studies in, 91–92
Burkitt's lymphoma, cellular oncogenes in, 174
Burns, immunoglobulin levels and, 454–455
Business consultation, for office testing, 214
Business plan, in office testing, 214

C3 complement, electrophoretic screening for abnormal levels of, 448
Calibration work record, in quality control, 627–630
Cancer, lactate dehydrogenase levels in, 542
Caprine arthritis-encephalitis virus, in rheumatoid arthritis, 29
Carcinoembryonic antigen, as screening test, 247
Carcinogenesis, oncogene activation in, 176
Carcinoma, serum immunoglobulin E and, 119
Cardiac contusion, serum creatine kinase levels in, 560
Cardiac disease, adult serum alkaline phosphatase in, 528–529
Cardiac surgery, serum creatine kinase levels following, 562–563
Cartilage, in rheumatoid arthritis, 34–35
Cell-mediated immune mechanisms, in rheumatoid arthritis, 32–38
Cells, oncogenes in, 169
Cellulose acetate electrophoresis, of amylase isoenzymes, 592, 593
versus agarose, 403–407
Central nervous system, in multiple sclerosis, 105–106
Cerebrospinal fluid, and creatine kinase levels following head injury, 560–561
electrophoresis of, immunofixation electrophoresis as adjunct to, 604
immunoglobulins of, origins of, 462
in multiple sclerosis, 107–111
proteins of, **457–475**
quantitative IgG changes in, 460–462
Cerebrospinal fluid albumin–to–serum albumin ratio, as index of blood-brain barrier integrity, 459
Ceruloplasmin, disorders associated with decrease in, 446
Chemistry, clinical, quality control and assurance in. See *Quality control and quality assurance, in clinical chemistry.*
dry. See *Dry chemistry*.
Chemistry analyzers, for doctor's office testing, 311–315
Chemistry profiles, 250
Chemotaxis, complement system and, 142
ChemPro-1000 system, 311–312
Chemstrips bG, 230
Chemstrip(s) LN, 295
Chemistrip(s) uG, 221
Children, acquired immune deficiency syndrome in, 4–5
benign chronic bullous disease of, immunofluorescent studies in, 95
Chlamydia trachomatis, direct detection of, 299–300
Chlamydiazmye test, 299
Cholesterol, total, test of, 251
Chorionic gonadotropin, human, in urine, in pregnancy, 262–263
Chromatography, column, for separation of creatine kinase isoenzymes, 567
in measurement of serum creatine kinase, 553
ion-exchange, for measurement of amylase isoenzymes, 593–594
Chromosomal localization, of cellular oncogenes, 169–171
Circulating factors, blood, 157–158
Cirrhosis, beta-gamma bridge and, 449
of liver, polyclonal gammopathy and, 449, 450
serum intestinal alkaline phosphatase and, 500
CK-MB test for acute myocardial infarction, false-positive, common causes of, **577–581**
Cleavage, of complement components, assays for, 148–149

Clinical considerations, in office testing, 213
Clinical laboratorian, in in-office testing, 211–212
Clinical laboratory(ies), biohazard control in, 792–793
  federal regulation of, 372, 373
  fire emergency preparedness in, 791-792
  hazardous waste management in, 794–796
  historical background of, 370–371
  radionuclide considerations in, 793–794
  regulation of, evolution of, 371–372
  reporting of accidents and illnesses in, 796–797
  safe work practices in, documentation of, **787–798**
    regulatory overview of, 787–788
    use of toxic chemicals and, 793
  safety manual for, 788–791
  state regulation of, 379–381
Clinical Laboratory Improvement Act (CLIA), regulations of, 318, 319, 371, 375
Clinical laboratory tests, accuracy of, 356–357
  performance characteristics of, 357–358
  performance of, evaluations of, 364–365
  proliferation of, clinicians and, 362
  purposes of, 356–357
  reference standards for, 365–366
  repetition of, 360
  results, effect of, on patient management, 360–361
    "normal" and "abnormal", 358–360
    reporting schemes for, 364
  strategies of, 361–362
Clinician(s), collaboration of pathologist with, in changing environment, 362–366
  education of, by clinical laboratory pathologists, 363, 366
CLINILAB, 264
Clinistix, 220–221
CLINI-TEK, 264
Clinitest, 218–219, 267–268
Coagulation, immunology and, **157–165**
  testing, 281–284
    instruments for, 282–283
  in renal disease, 59
Competitive binding radioimmunosorbent test, for serum immunoglobulin E, 121
Complement, C1q binding test, in renal disease, 62
  coagulation and, 159–160
Complement activation, assays for, **139–155**
Complement band, in diagnosis of systemic lupus erythematosus, 408
Complement system, in renal disease, 55–57
CompreCare, 339
Congenital atransferrinemia, serum protein electrophoresis and, 447
Copper reduction technique, in diabetes mellitus, 218–220
Coronary bypass surgery, serum creatine kinase levels following, 562–563
Cost containment, and physician practice, 339–342
Cost effectiveness, definition of, in laboratory setting, 756–757
Creatine kinase, and causes of false-positive test for myocardial infarction, **577–581**
  molecular forms of, 547–549
  serum, pathologic conditions causing changes in, 556–564
  variant bands of, 578–580
Creatine kinase complexes, types I and II macro, 578–580
Creatine kinase isoenzymes, **547–576**
Crescentic glomerulonephritis, 71
Crossmatching, in blood banks, 694–696
CSF. See *Cerebrospinal fluid*.
Cushing's syndrome, immunoglobulin levels and, 455
Cutaneous immunofluorescence, **85–102**
Cytoid bodies, immunofluorescence of, 98
Cytomegalovirus, in acquired immune deficiency syndrome, 15, 19
Cytopathology, quality control and assurance in. See *Quality control and assurance, in cytopathology*.
Cytoplasmic creatine kinase, 547–548
  tissue activities of, 549–550
Cytoplasmic fluorescence, 98
Cytotoxic cells, in rheumatoid arthritis, 33

Delta check system, 718–720
Demyelination, autoimmune, viruses and, 468
  in multiple sclerosis, 105–106
  primary, 457
Densitometers, in electrophoresis, 420–423
Densitometry, and problems in the electrophoretic process, 432–438
Deoxyribonucleic acid, antibodies to, 46
  hybridization techniques, 107
  viral oncogenes and, 167–169
Dermatitis herpetiformis, immunofluorescent studies in, 94
Dermatomyositis, serum creatine kinase levels in, 559
Dextrostix, 228, 267–268
Dextrostix look-alikes, 228–230
Diabetes mellitus, elevated alkaline phosphatase in, 528
  home monitoring of, **215–239**
  screening for, 250–251
  urine glucose monitoring, 215–218
  urine testing methods, 218–221

Diagem, 235
Diarrhea, in acquired immune deficiency syndrome, 6
Diascam, 234
Diastix, 221
Diffusion, in immunofixation electrophoresis, 413–414
Dilution effect, on serum proteins, 428
Discoid lupus erythematosus, immunofluorescent studies in, 89
Disease(s), asymptomatic, screening, 242
  complement system and, 141–142
  diagnosis of, value of advancing time of, 242–243
  natural history of, and efficacy of therapy, 242–243
  prevalence, and predictive value of positive test, 246
Doctor's office testing. See *Office laboratories* and *Office testing*.
Double antibody assay, for serum immunoglobulin E, 121
Drugs, and serum creatine kinase levels, 563
Dry chemistry, benefits of, in office, 269
  future for, 270–271
  historical background of, 267–271
  limitations of, in office, 269–270
  reagent systems, 268–269
Duchenne's muscular dystrophy, CK-MB elevation in, 577–578
  creatine kinase activity in, 551–552, 559

Eczema, serum immunoglobulin E and, 121
Education, for office testing, 213, 390–391
Ektachem DT-60 analyzer, 312–313
Ektachem DTE module system, 312–313
Electroendosmosis, of agarose, 405, 406
Electroimmunoassay, for activation-dependent protein-protein complexes, 151
Electron microscopy, in renal disease, 61–62
Electrophoresis, acrylamide, of amylase isoenzymes, 591, 593
  cellulose acetate, of amylase isoenzymes, 592, 593
  for complement component cleavage, 148
  immunofixation, usefulness of, in clinical laboratory, **601–605**
  in oncogene identification, 184—187
  of cerebrospinal fluid, immunofixation electrophoresis as adjunct to, 604
  problems of, 429–432
  protein, immunofixation electrophoresis as adjunct to, 602–604
  support media, 403–407
  techniques of, in clinical laboratory, **403–426**
Encephalomyelitis, experimental allergic, multiple sclerosis and, 106
Enterobacteriaceae, identification of, automated and rapid systems for, 652–653
  conventional methods for, 650–651
Environment, multiple sclerosis and, 104
Enzyme-linked immunosorbent assay, allergen-specific immunoglobulin G and, 133–134
  for activation-dependent protein-protein complexes, 152–153
  for histone antibodies, 47
  for membrane attack complex, 153
Enzyme-linked immunosorbent assay (ELISA), in group A streptococcal detection, 292
  in sexually transmitted diseases, 298–301
Enzymes, urine, assessment of, 262
Eosinophils, in renal disease, 58
Epidemiology, of acquired immune deficiency syndrome, 3–9
  of multiple sclerosis, 103–104
Epidermolysis bullosa, immunofluorescent studies in, 95–96
Epithelium, in alpha–heavy chain disease, 482–483
Epstein-Barr virus, acquired immune deficiency syndrome and, 20
Erythrocyte sedimentation rate, 284–286
Ethical factors, in acquired immune deficiency syndrome, 21
Exercise, and creatine kinase activity, 550–551, 554–556
Exfoliative dermatitis, immunoglobulin levels and, 454–455
Experimental allergic encephalomyelitis, multiple sclerosis and, 106
  viruses and, 468

Factor(s), blood, in coagulation, 157–158
Factor VIII inhibitor, in coagulation, 161–162
"Fast liver" alkaline phosphatase fraction, diagnostic use of, 515
Fecal occult blood testing, 286–289
  kits for, 288
Federal government, in regulation of laboratories, 372–376
Fibrinolytic system, in coagulation, 159
Financial incentives, laboratory test ordering and, 391–392

Gamma globulin, cerebrospinal fluid, in multiple sclerosis, 107
Gamma-glutamyltransferase, clinical significance of, 531
Gamma-glutamyltransferase isoenzymes, interpretation of electrophoretic patterns of, **533–540**

Gene sequence, and oncogene identification, 182–183, 186
Genomes, of viral oncogenes, 167–169
GGT_2 isoenzyme, alcoholic hepatitis and, 536–537
GGT_3 isoenzyme, adenocarcinoma of pancreas and, 538
alcoholic acute pancreatitis and, 537
Giemsa-stained smears, in herpes virus detection, 300
Glomerulonephritis, 64–76
Glucochek SC, 234
Glucochek II½, 234
Glucokey, 235
Glucometer, 231
Glucometer II, 234
Glucosan Plus, 234
Glucosan 2000, 234–235
Glucosan 3000, 234–235
Glucose monitoring, blood, at home, accuracy of, 225–226
adverse effects of, 226–228
efficacy of, 228
finger puncture aids for, 226–227
information derived from, 235–236
new directions in, 236–237
patient selection for, 225
rationale for, 224–225
record-keeping for, 225
reflectance meters for, 231–235
Glucose oxidase methods, in diabetes mellitus, 220–221
Glucose testing, urine, 215–218, 254–255
double-void technique for, 216
errors in, 223
patient selection for, 217–218
pluses vs. percentages in, 221–222
products, 218–221
rationale for, 218
record-keeping for, 223
sick days rules for, 218
when to test, 222
Glucose testing strips, blood, 228–231
Glucostix, 231
Gonodecten test, 299
Gonozyme test, 298–299
Goodpasture's syndrome, 71
Gram-negative rods, identification of, using commercial systems, 653–654
nonfermentative, identification of, systems for, 651
Growth factors, oncogenes and, 183

Haptoglobin, disorders associated with decrease in, 46
Head injury, serum creatine kinase levels in, 560–561
Health maintenance organizations (HMOs), 336–339
cost-containment efforts of, 340
office testing and, 338–339
service utilization and setting of care in, 338
Health Planning and Resources Development Act of 1974, "Certificate of Need" and, 375
Heat treatment, in pre-electrophoresis of alkaline phosphatase, 515
Hematocrit, measurement of, 276–278
Hematology, quality control and assurance in. See *Quality control and assurance, in hematology.*
Hematology analyzers, 274–275
Hematology instrument(s), multichannel, quality control of, 726–728
Hematology testing, in office, **273–289**
Hemoglobin, measurement of, 276–278
chemistry analyzers for, 277
Hemolytic anemia, lactate dehydrogenase level in, 542
serum protein electrophoresis of beta globulins and, 447
Hemopexin, abnormalities associated with decrease in, 448
Hemophilia, acquired immune deficiency syndrome and, 8
factor VIII inhibitor in, 161–162
Henoch-Schönlein syndrome, 69–71
Hepatic cancer, high–molecular weight alkaline phosphatase in, 499
Hepatic disease, adult serum alkaline phosphatase in, 526–527
beta-gamma bridge and, 449
decreased $alpha_1$ globulin and, 444
transferrin levels and, 447
Hepatitis, viral, acute, lactate dehydrogenase levels in, 542, 543
Herpes gestationis, immunofluorescent studies in, 96
Herpes simplex virus infection, rapid detection of, 300–301
Heyman's nephritis, 66
High–molecular weight alkaline phosphatase, 495–497, 518
in liver cholestasis, 497–499
polyacrylamide gels and, 515
Histones, antibodies to, 46–47
Histoplasmosis, in acquired immune deficiency syndrome, 6
Hodgkin's disease, lactate dehydrogenase levels in, 544
polyclonal gammopathy and, 450–451
Hodgkin's disease, serum immunoglobulin E and, 119
Home laboratory testing, quality assurance in, **799–803**

Home monitoring, of diabetes mellitus, **215–239**
Hospital laboratorian, in office testing, 212
Hospital laboratory, role of, in office testing, 211–214
HTLV-III/lymphadenopathy-associated virus, in acquired immune deficiency syndrome, 6–10, 16–20
Hypergammaglobulinemia, beta-gamma bridge and, 449
Hyperlipidemia, screening for, 251
Hyperthyroidism, immunoglobulin levels and, 455
Hypoalbuminemia, electrophoretic pattern of, 443
Hypogammaglobulinemia, monoclonal gammopathy and, 453–454
Hypothryoidism, serum creatine kinase levels in, 559–560
Hysteria, vs. multiple sclerosis, 104

Iatron test system, for yeast identification, 661
IgA, cerebrospinal fluid levels of, in multiple sclerosis, 465
IgG, free light chains of, in multiple sclerosis, 467
  monoclonal gammopathy and, 451
  polyclonal gammopathy and, 449–451
  of the central nervous system, restricted heterogeneity of, in multiple sclerosis, 466–467
  origin of elevated levels of, in multiple sclerosis, 462
  qualitative abnormalities of, in cerebrospinal fluid, 463
IgG index, as measure of central nervous system IgG snythesis, 460–462
IgM, cerebrospinal fluid levels of, in multiple sclerosis, 465
Immune complexes, circulating, in renal disease, 62–63
Immune-complex glomerulonephritis, 64–65
Immune-induced nephritis, 64–67
Immune system, role in coagulation, 159–163
Immunoassay, of allergen-specific immunoglobulin G, 132–134
  of amylase isoenzymes, 594–595
  of serum complement, 146–147
  of total serum immunoglobulin E, 121–123
Immunoblot techniques, in oncogene identification, 186–190
Immunodiffusion assay, for C1-inhibitor function, 150–151
  in renal disease, 63
Immunoelectrophoresis, immunofixation
Immunoelectrophoresis *(Continued)*
  electrophoresis as adjunct to, 601–602
  steps of, 412, 413
  vs. immunofixation, 413–420
Immunoenzyme tests, in systemic rheumatic disease, 44–50
Immunoenzymetric methods, for separation of creatine kinase isoenzymes, 566–567
Immunofixation electrophoresis, as adjunct to electrophoresis of cerebrospinal fluid, 604
  as adjunct to immunoelectrophoresis, 601–602
  as adjunct to routine protein electrophoresis, 602–604
  usefulness of, in clinical laboratory, **601–605**
  vs. immunoelectrophoresis, 413–420
Immunofluorescence, cutaneous, 85–102
  in renal disease, 61
Immunofluorescence assay, in systemic rheumatic disease, 44–50
  of histone antibodies, 46–47
Immunogenetic mechanisms, in rheumatoid arthritis, 38
Immunoglobulin(s), deficiency of, serum immunoglobulin E and, 119
  in membranous glomerulonephritis, 72–73
  monoclonal, 409–416
  of cerebrospinal fluid, origin of, 462
  synthesis of, in central nervous system, 459–460
Immunoglobulin–alkaline phosphatase complexes, 501
Immunoglobulin-bound creatine kinase, 548–549
Immunoglobulin E, in allergic diseases, 117–130
Immunoglobulin G, allergen-specific, assay of, 130–134
  multiple sclerosis and, 105–106, 107, 109–111
Immunoglobulin G radioallergosorbent assay, for insect venom antibody, 133–134
Immunoinhibition, for separation of creatine kinase isoenzymes, 566
  in measurement of serum creatine kinase, 553
Immunologic abnormalities, systemic, in multiple sclerosis, 111–112
Immunologic disease, polyclonal gammopathy and, 450
Immunologic specificities, of antibodies to nuclear antigens, 45–49
Immunopathology. See specific diseases, assays, and immunopathologic phenomena.
Immunoprecipitation, for separation of creatine kinase isoenzymes, 566

Immunoproliferative small intestinal disease, 477, 478, 483
Immunoproteins, in renal disease, 60–61
Infection(s), complement system and, 142, 143
of upper respiratory tract, 291–294
of urinary tract, 294–297
Infectious agent(s), multiple sclerosis and, 104
rheumatoid arthritis and, 27–31
Inflammation, complement system and, 142–143
rheumatoid arthritis, **27–40**
Insect venom, immunoglobulin E and, 130
immunoglobulin G and, 131, 133–134
Instruments, doctor's office testing, 213
cost of, impact of, 308
criteria for evaluating, 306–307
description of, 305
for urine study, 263–264
selection of, **305–315**
Interleukin-2, in rheumatoid arthritis, 33
Intestinal alkaline phosphatase, 491, 492
diagnostic use of, 516–517
electrophoretic zone of, 512, 514
Intestinal alkaline phosphatase isoenzyme, 500
Iron deficiency anemia, decreased transferrin levels and, 447
Isoelectric focusing, for detection of oligoclonal bands in multiple sclerosis, 463–464
in measurement of amylase isoenzymes, 588–593
Isolator system, for detection of bacteremia, 661

Joints, in rheumatoid arthritis, **27–40**

Kaposi's sarcoma, in acquired immune deficiency syndrome, 6, 10–12, 15
"Kasahara" isoenzyme, of alkaline phosphatase, 518
Ketone bodies, description of, 223
urine testing for, 223–224, 260–261
drugs or conditions interfering with, 224
products used in, 224
systems for office use in, 261
Kidney(s), disease of, **55–83**
Kidney alkaline phosphatase, 515

Labor laws, laboratory practice and, 375–376
Laboratory(ies), clinical. See *Clinical laboratory(ies)*.
federal regulation of, current, 372–376
Laboratory(ies) *(Continued)*
history of, 371–372
hospital, role of, in office testing, 212
nonphysician, regulation of, 371–372
office. See *Office laboratory*.
state regulation of, 376–377, 379–381
Laboratory testing, in-office. See *Office testing*.
Laboratory tests, clinical. See *Clinical laboratory tests*.
incidence of use of, 387
increasing number of, 387
ordering of, factors influencing, 388–389
theories of physician behavior and, 389–390
utilization of administrative changes and, 392
audit with feedback and, 391
educational techniques and, 390–391
financial incentives and penalties and, 391–392
interventions to improve, 390
Lactate dehydrogenase isoenzymes, interpretation of, 541–545
Latex agglutination, in group A streptococcal detection, 292
in herpes virus detection, 301
Leukemia, chronic lymphocytic, immunoglobulin levels and, 454
lactate dehydrogenase levels in, 542
monocytic, pseudomonoclonal spike and, 451
Leukocyte(s), polymorphonuclear neutrophilic, in renal disease, 57
Leukocyte esterase, urinary, measurement of, 259
Leukocyte esterase test, in urinary tract infections, 295
Leukoencephalopathy, progressive focal, viruses and, 106
progressive multifocal, viruses and, 468
Leukosis virus, neoplasia and, 168–169
Lichen myxedematosis, monoclonal gammopathy and, 452
Light microscopy, in renal disease, 61–62
Light scatter, densitometry and, 432–433
Linear IgA dermatosis, immunofluorescent studies in, 95
Linearity, densitometry and, 435–436
Link IgG index, in multiple sclerosis, 108
Lipemia, and serum protein electrophoresis results, 428–429
Liver, cancer of, high–molecular weight alkaline phosphatase and, 496–497, 499
disease of, serum immunoglobulin E and, 121
Liver alkaline phosphatase, electrophoretic zone of, 511, 512
Liver cholestasis, alkaline phosphatase level in, 527

Liver cholestasis *(Continued)*
mechanism of high–molecular weight protein-lipid release in, 497–499
Liver disorders, decreased ceruloplasmin and, 446
high–molecular weight alkaline phosphatase and, 495–497
intestinal alkaline phosphatase in diagnosis of, 492
Lumac Biocounter, 296–297
Lung, creatine kinase activity in, 552
Lupus anticoagulant, 162–163
Lupus erythematosus, immunofluorescent studies in, 89–92
systemic. See *Systemic lupus erythematosus.*
Lupus glomerulonephritis, 76
Lymph nodes, in acquired immune deficiency syndrome, 9–12
Lymphocytes, in multiple sclerosis, 111
in renal disease, 59
in rheumatoid arthritis, 32–33
Lymphoepithelial lesions, of alpha–heavy chain disease, 483
Lymphoma(s), B-cell, in acquired immune deficiency syndrome, 15
Burkitt's, cellular oncogenes in, 174
Mediterranean type, 477–478, 483–485
non-Hodgkin's, in acquired immune deficiency syndrome, 6, 10
of alpha–heavy chain disease, 480–482
of gastrointestinal tract, 477–478
polyclonal gammopathy and, 450
primary small intestinal, 482

Macroamylase, 584
Macrophages, in renal disease, 57–58
Malignancy(ies), alkaline phosphatase levels in, 516, 529–530
amylase level in, 588
in acquired immune deficiency syndrome, 15–16
monoclonal gammopathy and, 452
serum creatine kinase levels in, 563–564
tissue activities of creatine kinase in, 552
Malignant monoclonal B-cell disease, immunoglobulin levels and, 454
Malpractice, in-office laboratories and, 377–382
Mast cell(s), immunoglobulin E and, 118–119
Marrow, bone, in acquired immune deficiency syndrome, 12
Masugi nephritis, 65–66
Medicaid, regulation of laboratory practice by, 371, 374–375
Medicare, prospective payment system of, cost-containment efforts of, 340
description of, 330–331
Medicare *(Continued)*
hospital use of outpatient technology and, 332–333
physician response to, 331–332
regulation of laboratory practice by, 371–374
Mediterranean-type lymphoma, 477–478, 483, 484–485
Membranoproliferative glomerulonephritis, 74–76
Membranous glomerulonephritis, 71–73
Metabolism, intracellular, alkaline phosphatase and, 501
Microbiologists, office vs. conventional lab performance, 351–352
errors by, sources of, 348
performance of, factors contributing to deterioration of, 351
strategies to improve, 351–352
training for, 350, 352–353
Microbiology, quality control and assurance in. See *Quality control and assurance, in microbiology.*
rapid methods in, in office, **291–304**
Microbiology testing, office, proficiency of, 345–354
MicroTrak Direct Specimen Test, 299–300
Minimonoclonal bands, detected by serum protein electrophoresis, 409–412
Mitochondrial creatine kinase, 548
pathologic conditions and, 564
Mixed bullous disease, immunofluorescent studies in, 94–95
Mixed connective tissue disease, immunofluorescent studies in, 92
Monitoring, home, of diabetes mellitus, **215–239**
Monoclonal antibodies, in oncogene detection, 181–183, 190–191
Monoclonal bands, 409–416
Monoclonal gammopathy(ies), 409–413, 451–455
Monocytes, in renal disease, 57–58
Multiple sclerosis, **103–116**
cerebrospinal fluid proteins in, **457–475**
electrophoretic pattern in, 463
free IgG light chains in, 467
intrathecal Ig synthesis and, 459–460
origin of elevated IgG in, 462
qualitative abnormalities of IgG in, 463
quantitative IgG changes in, 460–462
restricted heterogeneity of IgG in, 466–467
viruses and, 468–470
Muscle, cardiac, creatine kinase activity in, 549–550
serum creatine kinase following exercise and, 555–556
skeletal, creatine kinase activity in, 549, 550–551

Muscle *(Continued)*
serum creatine kinase following exercise, and 554–556
serum creatine kinase in disorders of, 558–563
Muscular dystrophies, serum creatine kinase levels in, 559
Mutation, of cellular oncogenes, 171–175
Myelin basic protein, in multiple sclerosis, 110–111
Myelin sheaths, in multiple sclerosis, 105–106
Myeloma, multiple monoclonal gammopathy and, 451, 452
serum protein electrophoresis in detection of, 409–412
Myocardial contusion, serum creatine kinase levels in, 560
Myocardial infarction, acute, alkaline phosphatase in, 528
lactate dehydrogenase level following, 542, 544
Myocardium, creatine kinase activity in, 550
serum creatine kinase following exercise and, 554–556
Myometrium, creatine kinase activity in, 550

Nagao's isoenzyme, 517, 530
National Labor Relations Act (NLRA) laboratories and, 375–376
Negligence, activities and functions at risk for, 382
Neisseria, identification of, systems for, 658
Neisseria gonorrhoeae, rapid detection of, 297–299
Neoplasia, oncogene-related urine proteins in, **181–196**
oncogenes and, **167–179**
Neoplasms, alkaline phosphatase level in, 529
Nephritis, Heyman's, 66
immune-induced, 64–67
Masugi, 65–66
tubulointerstitial, 66–67
Nephrotic syndrome, increased $alpha_2$ macroglobulin and, 445
serum transferrin level and, 447
Neuraminidase, in electrophoresis of alkaline phosphatase, 512, 513, 515
Nitrite tests, in urinary tract infections, 258, 295
Nodular lymphoid hyperplasia, in alpha–heavy chain disease, 483
Noncompetitive binding radioimmunosorbent test, for serum immunoglobulin E, 121
Nonhistone proteins, antibodies to, 47–48
Nuclear fluorescence, 97
Nucleolar antigens, antibodies to, 48–49
5′-nucleotidase, clinical significance of, 530–531

Occupational Safety and Health Act (OSHA) regulations, 376
Office laboratory(ies), "acceptable" results from, criteria associated with, 321–322
changing environment of, 382–385
characteristics of, 806–808
future for, 385–386
legal definitions of, 317
malpractice and, 377–382
quality control in, **805–813**
problems related to, 811–812
quality of, 808–812
regulation of, federal, 372–376
forces promoting decreased, 384–385
forces promoting greater, 382–384
in Pennsylvania, 346–348
issues and trends in, **369–386**
state, 376–377, 379–381
Office testing, as benefit to physician, 206
as benefit to society, 206
as convenient to patient, 205–206
business consultation for, 214
business plan for, 214
clinical considerations in, 213
cost-reimbursement considerations associated with, 207
dry chemistry in, 267–271
economic basis of, 317
educational demands of, 213
hematologic, **273–289**
impact of reimbursement changes on, **329–343**
instruments and kits for, 213, **305–315**
microbiologic, **291–304**
proficiency of, **345–354**
patterns, evaluation of, **387–394**
variations in, 393
problems associated with, 208–209
quality control and quality assurance in, **317–327**
rapid diagnosis and treatment with, 207
rationale for, 205–209
regulation and reimbursement of, 212–213
role of clinical pathologist in, **355–368**
role of hospital laboratory and personnel in, **211–214**
systems available for, 208
troubleshooting associated with, 213
urinalysis in, **253–266**
when to do, 206–208
Oligoclonal IgG bands, detection of, in cerebrospinal fluid, 463–465
Oligoclonal band testing, in multiple sclerosis, 109

Oncogenes, neoplasia and, **167–179**
Optic neuritis, primary, oligoclonal IgG bands and, 465
Ortho Diagnostic test, in herpes virus detection, 300–301
Osseous disease, alkaline phosphatase level in, 527–528
Osteoporosis, alkaline phosphatase bone isoenzyme and, 500

PAGE. See *Polyacrylamide gel electrophoresis.*
Pancreatic GGT_3 isoenzyme, 537–538
Pancreatic insufficiency, amylase level in, 587–588
Pancreatic pseudocyst, amylase level in, 588
Pancreatitis, acute, amylase level in, 587
Panencephalitis, subacute sclerosing, viruses in, 106
Parasitic infection, serum immunoglobulin E and, 119
Parvovirus, in rheumatoid arthritis, 30
Pathologist(s), clinical laboratory, education of clinicians by, 363
information management by, 363–364
role of, in office testing, **355–368**
collaboration with clinician, in changing environment, 362–366
Pathology, anatomic, quality assurance in. See *Quality assurance, in anatomic pathology.*
Pemphigus, immunofluorescent studies in, 93–94
Peptides, in renal disease, 59–60
synthetic, in tumor detection, 181–183
Peripheral blood smear, 279–281
pH, of urine, assessment of, 257–258
Phadebas radioallergosorbent test, for immunoglobulin E, 124–127
Photometry, reflectance, 268
Physician, responsibility and obligation of, in office testing, 211
Physicians Health Plan of Minneapolis, 339
Plasma cell(s), in alpha–heavy chain disease, 483
Plasma cell dyscrasia, monoclonal gammopathy and, 451
Plasmacytosis, 479
Platelets, in coagulation, 159
in renal disease, 58–59
Platelet count(s), 273–276
Pneumocystis carinii pneumonia, in acquired immune deficiency syndrome, 3
Polistes wasp venom inhibition assay, 130–131
Polyacrylamide gel electrophoresis, for alkaline phosphatase isoenzymes, interpretation of, 494–500
for alkaline phosphatase isoenzyme separation, 493–494, 510
of acid phosphatase, 519, 520
Polyclonal gammopathy, 449–451
Polymorphonuclear neutrophilic leukocytes, in renal disease, 57
Polymyositis, serum creatine kinase levels in, 559
Ponceau S, in serum protein electrophoresis prestaining, 429
Porphyria, immunofluorescent studies in, 96
Posture, and serum protein electrophoresis results, 429
Prealbumin, electrophoretic pattern of, 442–443
Predictive value positive and predictive value negative, 244–245
Preferred provider organizations (PPO), 333–336
cost-containment efforts of, 339–340
implications of, for office testing, 334–336
Pregnancy, alkaline phosphatase level during, 525
herpes gestationis in, immunofluorescent studies in, 96
oncogene-related urine proteins in, **181–196**
serum amylase activity during, 586–587
serum creatine kinase activity during, 556
Pregnancy tests, urine, 262–263
Prestaining for electrophoresis, problems of, 429–430
Progressive focal leukoencephalopathy, viruses in, 106
Progressive multifocal leukoencephalopathy, viruses and, 468
Proliferative glomerulonephritis, 67–70
Prompt bench-top analyzer, 313
Prostaglandins, in renal disease, 60
Protein(s), alpha–heavy chain disease, 478–479
blood, 157–158
myelin basic, in multiple sclerosis, 110–111
nonhistone, antibodies to, 47–48
of cerebrospinal fluid, in multiple sclerosis, **457–475**
oncogene-related, in pregnancy and neoplasia, **181–196**
plasma, reaction mechanisms and, 139–141
serum, electrophoretic patterns of, 407–413
interpretation of, 441–455
Protein A solid phase radioimmunoassay, for allergen-specific immunoglobulin G, 132
Protein bands, normal, 407
Protein inhibitors, in measurement of amylase isoenzymes, 594
Protein-protein complexes, activitation-

Protein-protein complexes *(Continued)*
dependent, assays for, 150–153
Protein tests, urine, 255
Pulmonary infarct, acute, alkaline phosphatase level in, 529
Pyuria, rapid screening methods for, 296

Quality assurance, definition of, 318, 697, 745–746, 755
in a large reference laboratory, **745–754**
indirect factors affecting, 746–747
environment in, 752–753
personnel in, 748–750
process of, 747–748
in anatomic pathology, **697–706**
diagnostic report in, 699–701
instrument maintenance in, 699
role of pathologist in, 701–703
specimen identification and handling in, 698
tissue processing and procedure manuals in, 698–699
in cytopathology, 704–705
in home laboratory testing, **799–803**
elements of, 800–802
legal implications, 802
in the office laboratory, 809
mandatory, legal basis of, 318–319
of analytic process, **613–623**
alternative site testing in, 620–621
information sources for, 621–622
phases of testing in, 618–620
reference ranges in, 614–616
test selection in, 616–618
program(s), elements of, 319–321
in hospital, 212
reagents and equipment, for blood banks, 690–691
Quality control and quality assurance, in office testing, 317–327
clinical laboratory perspective of, 757–758
common errors in performance of, 772–773
computer-assisted, considerations for program design, **735–743**
general considerations for data files, 736–737
hardware for, 736
individual patient results in, checks on, 742
result input in, 738–739
result output in, 739–740
run evaluation in, 740–741
rules for, 741
underlying principles of, 735–736
controlling cost of, **755–785**
computers in, 781–782
strategies for, 773–782
with improved instrument precision, 780–781

Quality control and quality assurance *(Continued)*
current state of, **§15–818**
definition of, 318, 613–614, 697, 745–746, 755–762, 815
excessive cost of, factors contributing to, 765–773
in blood bank, **689–696**. See also *Blood bank(s)*.
in clinical chemistry, **625–648**
Calibration Work Record in, 627–630
quality control logs in, 630–644
in cytopathology, **707–713**
diagnostic accuracy in, 711–713
initial evaluation in, 709–711
role of cytotechnologist in, 709–710
specimen collection in, 707–708
specimen identification in, 708–709
specimen processing and staining in, 709
in hematology, **675–688**
acceptable limits used in, 685
external, 684–685
internal, 675–684
analytic steps, 677–682
postanalytic steps, 682–684
preanalytic steps, 676–677
of multichannel hematology instruments, averages of patient red cell indices for, 726–728
in microbiology, **649–674**
bacterial identification systems in, 650–662
product index for, 662–664
in the office laboratory, **805–813**
medical utility vs. analytic precision criteria in, 762–765
patient data for, **715–733**
critical value list for, 717
delta check system for, 718–720
use of averages of, 720–728
multivariate checks of, 728–732
program, daily, 322
establishment of, 322–326
Quality control, regulatory perspective of, 758–761
routine, 324–325
vendor perspective of, 761–762
Quality control systems, in a large reference laboratory, 750–752

Radioallergosorbent test, for immunoglobulin E, 123–130
Radioallergosorbent test inhibition assay, in allergic diseases, 130
Radioimmunoassay, for activation-dependent protein-protein complexes, 151–152
for complement component cleavage, 149
for separation of creatine kinase isoenzymes, 567

Radioimmunoassay *(Continued)*
in measurement of serum creatine kinase, 553–554
Radioimmunoprecipitation assay, for allergen-specific immunoglobulin G, 132
for serum immunoglobulin E, 121
Radioimmunosorbent test, for serum immunoglobulin E, 121
Raji cell assay, in renal disease, 63
Reagent(s), expired, use of, in controlling cost of quality control, 771–772
Red-cell acid phosphatase, 519
Reference normal value(s), in quality control, establishment of, 630
Reference range(s), in quality assurance, 614–616
Reflectance meters, 231–235
Reflectance photometry, 268
Reflotron reflectrance photometer, 313–314
Regan's isoenzyme, 517, 529, 530
Regulation, in medicine, dilemma of, 370
of doctor's office testing, 212
issues and trends in, **369–386**
Reimbursement, office testing and, 207, 212–213
reforms, impact of, on office testing, **329–343**
Renal disease, **55–83**
Renal glucose threshold, in diabetes mellitus, 215–216
Respiratory tract, upper, infections of, 291–294
Retrovirus(es), and oncogenes, 182
Reverse transcriptase, in acquired immune deficiency syndrome, 16–17
Rhabdomyolysis, lactate dehydrogenase level in, 542, 543
serum creatine kinase levels in, 558–559
Rheumatic disease, systemic, **41–53**
Rheumatoid arthritis, **27–40**
immunofluorescent studies in, 92–93
serum immunoglobulin E and, 121
Risk factors, of acquired immune deficiency syndrome, 8–9
of multiple sclerosis, 103–104

Safe work practices, documentation of, in clinical laboratory, **787–798**
Safety manual, for clinical laboratories, 788–791
Sarcoma, Kaposi's, in acquired immune deficiency syndrome, 6, 10–12, 15
Sarcoma virus, neoplasia and, 168
Scatter effect, densitometry and, 432–433
Scleroderma, immunofluorescent studies in, 92
polyspecificity of antibodies in, 43
Sclerosis, multiple. See *Multiple sclerosis*.
Screening of healthy subject, **241–252**
characteristics of disease and, 242–244
decision for, characteristics of patient and, 249
rationale for, 241–242
tests for, characteristics of, 244–248
Screening tests, accuracy of, 244
appropriate, selection of, 249–251
precision of, 244
sensitivity of, 244–245
specificity of, 244–245
Seralyzer system, 314
Serum, complement levels in, 146–147
immunoglobulin E in, 117–123
Serum albumin, abnormalities of, electrophoretic screening for, 441–443
in renal disease, 63
Serum proteins, and isoenzymes, electrophoresis of, **403–605**
Serum protein electrophoresis, interpretation of patterns, **441–455**
potential problems in, **427–440**
Serum total proteins, dilution effect and, 428–429
Sexual contact, and acquired immune deficiency syndrome, 8–9
Sexually transmitted diseases, detection of, 297–301
Shewhart multirule(s), in quality control, 758
Skin, immunofluorescent studies of, **85–102**
SPE. See *Serum protein electrophoresis*.
Specimen(s), handling of, in quality control in cytopathology, 707–709
Specimen(s), preparation for immunofluorescent studies, 85–86
Spleen, in acquired immune deficiency syndrome, 12
Staining, in electrophoretic process, 430–432
Staphylococcus, identification of, systems for, 655–656
Starch gel electrophoresis, of acid phosphatase, 519, 520
State regulation of laboratories, 376–377, 379–381
Stratum corneum fluorescence, 97
Streptococcus, group A, detection of, 292–294
identification of, systems for, 656–657
Subacute cutaneous lupus erythematosus, immunofluorescent studies in, 91
Subacute sclerosing panencephalitis, viruses in, 106
Support media, electrophoretic, 403–407
Synovium, in rheumatoid arthritis, 33–38
Systemic amyloidosis, monoclonal gammopathy and, 451, 452
Systemic lupus erythematosus (SLE), electrophoretic pattern of, 408–409
immunofluorescent studies in, 90–91
polyspecificity of antibodies in, 42–44
Systemic rheumatic disease(s), **41–53**

Tandem Icon Test, 263
T cells, in acquired immune deficiency syndrome, 14
Test(s). See *Clinical laboratory tests* and *Screening tests*.
Testape, 221
Testing, alternative site, 620–621
  phases of, 618–620
Testing cycle, identification of error in, 616–617
Throat culture, in group A streptococcal pharyngitis, 292
Thymus, in acquired immune deficiency syndrome, 12–14, 20
Tissue(s), cellular oncogenes in, 171
  complement component deposition in, 147
  immunofluorescent techniques in, 86
T-lymphocytes, in rheumatoid arthritis, 33–34
Tofranil, and gamma-glutamyltransferase isoenzyme induction, 539
Tourtellotte formula, in multiple sclerosis, 108
Transcriptional activation, of oncogenes, 175
Transfection studies, in oncogene identification, 175, 182–183
Transferrin, and iron deficiency, 447
Transfusion(s), and acquired immune deficiency syndrome, 9
  quality assurance in, in blood banks, 692–694
Trauma, caused by cardiac surgery, and serum creatine kinase levels following, 562–563
  caused by noncardiac surgery, and serum creatine kinase levels following, 561–562
  serum creatine kinase levels in, 560
Trendsmeter, 235
Triclonal gammopathies, 417
Triglycerides, and serum protein electrophoresis results, 428–429
TRIS-borate buffer, for alkaline phosphatase isoenzyme separation, 493
TRIS-borate-$MgCl_2$ buffer, in electrophoresis of alkaline phosphatase, 510
T-suppressor cells, in multiple sclerosis, 112
Tubulointerstitial nephritis, immunologically induced, 66–67
Tubulointerstitial renal disease, 78
Tumor(s), creatine kinase activity in, 552
  markers for, 181–182

"Umbrella effect," in immunofixation electrophoresis, 414–415, 602
UniPak-500 analyzer, 314–315
Uni-Yeast-Tek system, 660
Urinalysis, as monitor of wellness, 264–265
  basis for, in office laboratories, 254
  bilirubin tests in, 258–259
  enzyme studies in, 262
  for ketone bodies, patient selection for, 223–224
  historical background of, 253–254
  in office, advantages and limitations of, 265
  instrumentation for, 263–264
  ketone bodies measurements in, 223–224, 260
  leukocyte esterase measurements in, 259
  nitrate tests in, 258
  occult blood test in, 255–256
  role of, in physician's office, **253–266**
  urine glucose test in, 254–255
  urine pH and, 257–258
  urine protein tests in, 255
  urine sediment studies in, 260–262
  urine specific gravity measurement and, 256–257
  urobilinogen testing in, 259–260
Urinary tract, infections of, 294–297
Urine, components of clinical interest, 264
  enzymes, assessment of, 262
  oncogene-related proteins in, in pregnancy and neoplasia, **181–196**
  pH of, 257–258
  sediment, study of, 260–262
  testing, See *Urinalysis*.
Urine glucose testing. See *Glucose testing, urine*.
Urine pregnancy tests, 262–263
Urine specific gravity, 256–257
Urine testing methods, in diabetes mellitus, 218–221
Urobilinogen, urine, testing for, 259–260

Vasculitis, cutaneous, immunofluorescent studies in, 97
Vendors, of in-office equipment, 211
Virogen Herpes Slide Test, 301
Viruses, and multiple sclerosis, 468–470
  caprine arthritis-encephalitis, in rheumatoid arthritis, 29
  Epstein-Barr, acquired immune deficiency syndrome and, 20
  HTLV-III/lymphadenopathy-associated, in acquired immune deficiency syndrome, 6–10, 16–20
  in rheumatoid arthritis, 29–31
  leukosis, neoplasia and, 168–169
  multiple sclerosis and, 106
  oncogenes in, 167–169
  sarcoma, neoplasia and, 168

Visidex II, 230–231
Vision bench-top analyzer, 315

Waldenström's macroglobulinemia, monoclonal gammopathy and, 451, 452
Western-type primary small intestinal lymphoma, 485
Wheat-germ lectin, in electrophoresis of alkaline phosphatase, 512
White blood cell count(s), 273–276
Wilson's disease, decreased ceruloplasmin and, 446

Yeast(s), identification of, kits for, 660–661

Zone electrophoresis, 403–407
Zone truncation, densitometer and, 434–435